The activation of adiponectin and FXR expression in hepatic tissue may be a major mechanistic signaling cascade supporting the promising role of AO in NAFLD pharmacotherapy. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.